Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial.
Fiche publication
Date publication
octobre 2018
Journal
American journal of obstetrics and gynecology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VILLENA Isabelle
Tous les auteurs :
Mandelbrot L, Kieffer F, Sitta R, Laurichesse-Delmas H, Winer N, Mesnard L, Berrebi A, Le Bouar G, Bory JP, Cordier AG, Ville Y, Perrotin F, Jouannic JM, Biquard F, d'Ercole C, Houfflin-Debarge V, Villena I, Thiébaut R,
Lien Pubmed
Résumé
The efficacy of prophylaxis to prevent prenatal toxoplasmosis transmission is controversial, without any previous randomized clinical trial. In France, spiramycin is usually prescribed for maternal seroconversions. A more potent pyrimethamine + sulfadiazine regimen is used to treat congenital toxoplasmosis and is offered in some countries as prophylaxis.
Mots clés
pregnancy, prenatal diagnosis, pyrimethamine-sulfadiazine, spiramycin, tolerance, toxoplasmosis
Référence
Am J Obstet Gynecol. 2018 10;219(4):386.e1-386.e9